Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination regimen consisting of three drugs: - **Cyclophosphamide** is an alkylating agent used as chemotherapy, primarily for its cytotoxic effects on rapidly dividing cells. It crosslinks DNA, leading to cell death. - **Goserelin** and **leuprorelin (leuprolide)** are both gonadotropin-releasing hormone (GnRH) agonists. They act by initially stimulating, then downregulating the pituitary GnRH receptors, resulting in decreased secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to suppression of ovarian or testicular steroidogenesis and a reduction in circulating estrogen or testosterone levels. The combination of these agents may be used in clinical settings where both cytotoxic chemotherapy and profound hormonal suppression are desired—such as certain breast cancers in premenopausal women for ovarian protection during chemotherapy or advanced hormone-sensitive cancers[3][6][9]. Goserelin and leuprorelin have been shown to be comparable for ovarian protection during cyclophosphamide-based chemotherapy[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclophosphamide + goserelin + leuprorelin.